Vaccine myocarditis data

We urge governments to remove the COVID-19 mRNA products from the market, due to the well-documented risk of myocardial damage, a risk that is strongest for younger males ( under 40 years old). Independent Medical Alliance https://imahealth.org Senior Fellow of Paediatric Cardiology, Dr. Kirk Milhoan National News desk link https://www.youtube.com/watch?v=iAdYo0EJvkU Myocarditis after SARS-CoV-2 infection and COVID-19 vaccination: Epidemiology, outcomes, and new perspectives International Journal of Cardiovascular Research & Innovation (OPEN ACCESS) https://cardiovascular-research-and-innovation.reseaprojournals.com/Articles/myocarditis-after-sars-cov-2-infection-and-covid-19-vaccination-epidemiology-outcomes-and-new-perspectives Myocarditis, typically manifesting as myopericarditis, is among the serious cardiac consequences observed over the course of the COVID-19 pandemic. A comprehensive, evidence-based literature synthesis Clinical trial data reanalyses Post-marketing surveillance Large observational studies Epidemiological, clinical, and immunological perspectives Phenomenon of myocarditis post SARS-CoV-2 infection versus COVID-19 vaccine-induced myocarditis. Conclusions refute several claims (1). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Omicron infections have caused more cases of myocarditis than the COVID-19 mRNA immunizations Refuted (2) mRNA vaccine-induced myocarditis is typically mild, transient, and rare, with no long-term sequelae Refuted (3) the risk-benefit calculus favors continued use of these products despite evidence of more iatrogenic (vaccine causes) cases Refuted Learn more about your ad choices. Visit megaphone.fm/adchoices